DuPont (DD)
NYSEMaterialsChemicalsSnapshot 2026-09-04
$131.59+0.35%
Close 2026-09-04 · 1-day change
NYSEMaterialsChemicalsSnapshot 2026-09-04
Research Workspace
Put DD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Recent financial performance freshly dropped to the bottom half of its industry.
View ThesisRevenue is contracting — down about 26% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on earnings delivery, the balance sheet, guidance credibility.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskDuPont's growth in aerospace and healthcare must continue to justify its current price. Revenue grew 4% year over year, and the last quarter beat estimates. It trades at 16× P/E versus a peer median of 17×, indicating the market prices in more growth than expected. The recent drop in financial performance to the bottom half of its industry poses a risk. Peer multiples imply a price about 37% below where it trades.
Trailing returns as of 2026-09-04. DD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering DD (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for DD in the last 4 months.
Continue this research
Compare DD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| DD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put DD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive profitable growth with margin expansion and productivity
Sustainability award supports margin expansion and productivity goals.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $131.59
The last 12 months of price, then the range of analyst 12-month targets from today’s $131.59.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Legal issues could impact cash flow and growth objectives.
Legal issues could impact cash flow and growth objectives.
Advances: Achieve slightly above 4% organic sales growth in 2026
Expansion supports organic sales growth objective.
Earnings and guidance reset expectations positively.
Advances: Raise full year 2026 adjusted EPS guidance to about $7.24 per share
Raised EPS guidance supports growth objectives.
Advances: Raise full year 2026 EPS guidance
EPS guidance aligns with growth objectives.
Advances: Align 2026 guidance with medium-term targets
Raising outlook aligns with medium-term growth targets.
